Is RANKL a potential molecular target in osteoarthritis?
Osteoarthritis and Cartilage · 2024-05 · 32 (5) · 493-500
DOI: 10.1016/j.joca.2023.10.010 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Osteoarthritis and Cartilage, 2024-05. Verfasst von Dzenita Muratovic und 2 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Orthopaedic & Trauma Research, The University of Adelaide, Adelaide, South Australia 5000, Australia; Biomedical Orthopaedic Research Grou…. Hauptthemen laut MEDLINE: Cartilage, Articular, Osteoarthritis. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Barwon Health Foundation, National Health and Medical Research Council.
Abstract (Originalsprache)
OBJECTIVE: Osteoarthritis (OA) is a disease of joints, in which the bone under the articular cartilage undergoes increased remodelling activity. The question is whether a better understanding of the causes and mechanisms of bone remodelling can predict disease-modifying treatments. DESIGN: This review summarises the current understanding of the aetiology of OA, with an emphasis on events in the subchondral bone (SCB), and the cells and cytokines involved, to seek an answer to this question. RESULTS: SCB remodelling across OA changes the microstructure of the SCB, which alters the load-bearing properties of the joint and seems to have an important role in the initiation and progression of OA. Bone remodelling is tightly controlled by numerous cytokines, of which Receptor Activator of NFκB ligand (RANKL) and osteoprotegerin are central factors in almost all known bone conditions. In terms of finding therapeutic options for OA, an important question is whether controlling the rate of SCB remodelling would be beneficial. The role of RANKL in the pathogenesis and progression of OA and the effect of its neutralisation remain to be clarified. CONCLUSIONS: This review further makes the case for SCB remodelling as important in OA and for additional study of RANKL in OA, both its pathophysiological role and its potential as an OA disease target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Orthopaedic & Trauma Research, The University of Adelaide, Adelaide, South Australia 5000, Australia; Biomedical Orthopaedic Research Group, Centre for Orthopaedic & Trauma Research, The University of Adelaid…
- Centre for Orthopaedic & Trauma Research, The University of Adelaide, Adelaide, South Australia 5000, Australia. Electronic address: david.findlay@adelaide.edu.au.
Förderung
- Barwon Health Foundation
- National Health and Medical Research Council
Zitieren
APA
Muratovic, D., Atkins, G. J., & Findlay, D. M. (2024). Is RANKL a potential molecular target in osteoarthritis?. Osteoarthritis and Cartilage, 32(5), 493-500. https://doi.org/10.1016/j.joca.2023.10.010
Vancouver
Muratovic D, Atkins GJ, Findlay DM. Is RANKL a potential molecular target in osteoarthritis?. Osteoarthritis and Cartilage. 2024;32(5):493-500. doi:10.1016/j.joca.2023.10.010
BibTeX
@article{Muratovic2024,
author = {Muratovic, Dzenita and Atkins, Gerald J and Findlay, David M},
title = {Is RANKL a potential molecular target in osteoarthritis?},
journal = {Osteoarthritis and Cartilage},
year = {2024},
volume = {32},
number = {5},
pages = {493--500},
doi = {10.1016/j.joca.2023.10.010}
}
EUVIMED